ngµç×ÓÓÎÏ·ÐÂÎÅÍøѶ£¨Í¨Ñ¶Ô±ÆÕÓ­çù¡¢¡¢³Â¼Ñçù¡¢¡¢Áº¾°ºê£©¿ËÈÕ£¬£¬
£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ³ÂÑǾü½ÌÊÚÍŶӵÄÒ»ÏîÑо¿ÏÔʾ£¬£¬
£¬È«ÇòԼĪÿÈýÃû¶ùͯÇàÉÙÄêÖоÍÓÐÒ»ÈË»¼ÓнüÊÓ£¬£¬
£¬Ô¤¼Æµ½2050Ä꣬£¬
£¬ÕâÒ»ÄêËê¶ÎµÄ½üÊÓ»¼²¡ÈËÊý½«Áè¼Ý7.4ÒÚÀý¡£¸ÃÑо¿×ÛºÏÁË1990ÄêÖÁ2023Äê¼ä£¬£¬
£¬È«Çò50¶à¸ö¹ú¼Ò¡¢¡¢276ÏîÑо¿¡¢¡¢540¶àÍòÃû¶ùͯÇàÉÙÄêµÄÊý¾Ý£¬£¬
£¬Í¬Ê±Í¨¹ýʱ¼äÐòÁÐÄ£×Ó׼ȷԤ²âÁËδÀ´30Äê¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂʵÄ×ßÊÆ¡£¸ÃÑо¿Õ¹ÏÖÁËÈ«Çò½üÊÓÎÊÌâµÄÑÏËàÏÖ×´ºÍδÀ´¿ªÕ¹Ç÷ÊÆ£¬£¬
£¬Îª¹«¹²ÎÀÉú¾öÒéÌṩÁËÖ÷ÒªÒÀ¾Ý¡£Ïà¹ØЧ¹ûÒÔ¡°Global Prevalence, Trend and Projection of Myopia in Children and Adolescents from 1990 to 2050: A Comprehensive Systematic Review and Meta-analysis¡±ÎªÌâ½ÒÏþÔÚÑÛ¿ÆÁìÓòȨÍþÆÚ¿¯¡¶Ó¢¹úÑÛ¿ÆѧÔÓÖ¾¡·¡£

ͼÐÎÕªÒª

Ä¿½ñ£¬£¬
£¬½üÊÓÒѳÉΪȫÇò¹«¹²ÎÀÉúµÄÖØ´óÌôÕ½Ö®Ò»£¬£¬
£¬Æ仼²¡ÂÊÔÚ¶ùͯÇàÉÙÄêȺÌåÖÐѸËÙÅÊÉý¡£Ñо¿ÍŶӲο¼ÁË×èÖ¹2023Äê6ÔµÄ45,470ƪÏà¹ØÑо¿ºÍÕþ¸®±¨¸æ£¬£¬
£¬»ùÓÚÑÏ¿áµÄÄÉÅűê×¼ºÍÖÊÁ¿ÆÀ¹À£¬£¬
£¬×îºóÄÉÈëÁýÕÖÀ´×ÔÑÇÖÞ¡¢¡¢Å·ÖÞ¡¢¡¢·ÇÖÞ¡¢¡¢´óÑóÖÞ¡¢¡¢±±ÃÀºÍÀ­¶¡ÃÀÖÞ50¸ö¹ú¼ÒµÄ276ÏîÑо¿£¬£¬
£¬5,410,945Ãû¶ùͯÇàÉÙÄ꣬£¬
£¬Éæ¼°1,969,090Ãû½üÊÓ²¡Àý¡£Ñо¿ÍŶÓÕûºÏÁËËùÓÐÕâЩÑо¿Êý¾Ý£¬£¬
£¬²¢Ë¼Á¿Á˵ØÀí¡¢¡¢Ê±¼äÒÔ¼°ÆäËü±äÁ¿£¬£¬
£¬Ê¹ÓÃËæ»úЧӦģ×ÓÔ¤¼Æ½üÊÓµÄ×ÜÌåÊ¢ÐÐÂʼ°Æäʱ¼äÇ÷ÊÆ£¬£¬
£¬½ÓÄÉ×Իعé»ý·Ö»¬¶¯Æ½¾ùÄ£×ÓÔ¤²â2050ÄêÈ«Çò¶ùͯÇàÉÙÄê½üÊÓÊ¢ÐÐÂÊ£¬£¬
£¬²¢Í¨¹ýµ÷½â©¶·Í¼ºÍEggerÄ¥Á·ÆÀ¹À½ÒÏþÆ«ÒС£

Ñо¿ÏÔʾ£¬£¬
£¬È«Çò¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂʵÄÔ¤¼ÆֵΪ30.5%£¬£¬
£¬²¢ÇÒÔÚÒÑÍù30Äê¼äÏÔÖøÔöÌí£¬£¬
£¬´ÓÔ¼ËÄ·ÖÖ®Ò»ÔöÌíµ½ÏÖÔÚµÄÈý·ÖÖ®Ò»£º1990-2000ÄêÈ«Çò¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂÊΪ24.3%£»£»2001-2010ÄêΪ25.3%£»£»2011-2019ÄêÔöÌíÖÁ29.7%£»£»2020-2023Äêʱ´ú£¬£¬
£¬½üÊÓÂʸüÊǼ±¾çÅÊÉý£¬£¬
£¬ÆäÖÐÇàÉÙÄêµÄ½üÊÓÂʸߴï54%¡£

¾­¼Ã¿ªÕ¹Ë®Æ½¶Ô½üÊÓ»¼²¡ÂÊÓÐÏÔÖøÓ°Ï죬£¬
£¬¿ªÕ¹Öйú¼Ò»ò²»Å¹ú¼ÒµÄ½üÊÓ»¼²¡ÂÊ£¨31.9%£©ÏÔןßÓÚÅ¹ú¼Ò£¨23.8%£©¡£ÆäÖУ¬£¬
£¬ÑÇÖÞµØÇøµÄ½üÊÓ»¼²¡ÂÊ×î¸ß£¬£¬
£¬µÖ´ï35.2%£»£»À­¶¡ÃÀÖ޺ͼÓÀձȵØÇø×îµÍ£¬£¬
£¬½öΪ3.8%¡£ÔÚ±¾Ñо¿°üÀ¨µÄ50¸ö¹ú¼ÒÖУ¨Í¼2£©£¬£¬
£¬ÈÕ±¾µÄ¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂÊ×î¸ß£¨86.0%£©£¬£¬
£¬Æä´ÎÊǺ«¹ú£¨73.9%£©¡¢¡¢¶íÂÞ˹£¨46.2%£©ºÍмÓÆ£¨44.1%£©£»£»ÖйúÅÅÔÚµÚÎå룬£¬
£¬Îª41.1%¡£

½üÊÓ»¼²¡ÂÊÔÚÄêËê¡¢¡¢ÐÔ±ðºÍµØÇø·½Ãæ²î±ðÒ²ºÜÊÇÏÔ×Å¡£ÕûÌå¶øÑÔ£¬£¬
£¬ÇàÉÙÄêµÄ½üÊÓ»¼²¡ÂʸßÓÚ¶ùͯ£¬£¬
£¬Ðè×¢ÖصÄÊÇ£¬£¬
£¬´Ó1990Äêµ½2023Ä꣬£¬
£¬¶ùͯ½üÊÓ»¼²¡Âʵľø¶ÔÔöÌíÂÊԼΪÇàÉÙÄêµÄÁ½±¶¡£ÐÔ±ð·½Ã棬£¬
£¬Å®º¢µÄ½üÊÓ»¼²¡ÂÊ£¨33.6%£©ÂÔ¸ßÓÚÄк¢£¨30.5%£©£¬£¬
£¬ÆäÖÐÇà´ºÆÚÅ®º¢µÄ½üÊÓ»¼²¡Âʵִï48.8%£»£»ÑÇÖÞÅ®º¢µÄ½üÊÓ»¼²¡ÂÊ£¨37.7%£©¸ßÓÚÑÇÖÞÄк¢£¨34.3%£©£¬£¬
£¬Æä´ÎÊDZ±ÃÀÖÞÅ®º¢£¨26.9%£©ºÍ±±ÃÀÖÞÄк¢£¨24.1%£©¡£³ÇÏç²î±ð·½Ã棬£¬
£¬³ÇÊеØÇø¶ùͯÇàÉÙÄêµÄ½üÊÓ»¼²¡ÂʸßÓÚÅ©´å£¬£¬
£¬²¢ÇÒ³ÇÊÐÅ®º¢µÄ½üÊÓ»¼²¡ÂÊ£¨32.0%£©¸ßÓÚÄк¢£¨29.4%£©¡£

È«Çò¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂÊÇéÐÎ

ÖйúÇéÐΣºÑо¿ÍŶӶÔÖйú¶ùͯÇàÉÙÄê½üÊÓÇéÐξÙÐÐÁ˵¥¶ÀÆÊÎö£¬£¬
£¬Í¼3ÏÔʾÁËÖйú¶ùͯÇàÉÙÄêµÄ½üÊÓ»¼²¡ÂÊÇéÐΡ£±¾Ñо¿¹²Éæ¼°1,891,986ÃûÖйú¶ùͯÇàÉÙÄ꣬£¬
£¬ÆäÖÐ4,294,116Ãû»¼ÓнüÊÓ¡£ÕûÌå¶øÑÔ£¬£¬
£¬1990Äêµ½2023ÄêÖйú¶ùͯÇàÉÙÄêµÄ½üÊÓ×Ü»¼²¡ÂÊΪ41.1%¡£²î±ðµØÇø¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂÊÓÐËù²î±ð£¬£¬
£¬¶«²¿µØÇø½üÊÓ»¼²¡ÂÊ×î¸ß£¬£¬
£¬Îª46.3%£»£»Æä´ÎÊÇÎ÷²¿£¨37.8%£©ºÍÖв¿µØÇø£¨37.1%£©£»£»ÌØÊâÐÐÕþÇø£¨±¾Ñо¿½öÉæ¼°ÖйúÏã¸ÛºÍÖйų́ÍåµØÇø£©Îª31.3%£»£»¶«±±²¿µØÇøΪ28.0%¡£¹ØÓÚÐÔ±ð²î±ð£¬£¬
£¬ÕûÌåÉÏÅ®º¢µÄ½üÊÓ»¼²¡ÂÊ£¨43.7%£©¸ßÓÚÄк¢£¨39.7%£©£¬£¬
£¬Êý¾ÝÏÔʾÓÈÆäÊǹãÎ÷Å®º¢µÄ½üÊÓ»¼²¡ÂʵִïÁË72.9%£¬£¬
£¬Æä´ÎÊǽ­ËÕÅ®º¢£¨67.4%£©ºÍÉÂÎ÷Å®º¢£¨61.7%£©¡£

δÀ´Ô¤²â£ºÆ¾Ö¤Ô¤²âÆÊÎöЧ¹û£¨±í1£©£¬£¬
£¬2030ÄêÈ«Çò¶ùͯÇàÉÙÄêµÄ½üÊÓ»¼²¡Âʽ«µÖ´ï32.2%£¬£¬
£¬Ô¤¼ÆÓ°Ïì½ü6ÒÚ¶ùͯÇàÉÙÄꣻ£»2040Äê½üÊÓ»¼²¡Âʽ«ÉÏÉýÖÁ36.6%£¬£¬
£¬Ô¤¼ÆÓ°ÏìÁè¼Ý6.6ÒÚ¶ùͯÇàÉÙÄꣻ£»2050Äê½üÊÓ»¼²¡Âʽ«¼ÌÐøÉÏÉýÖÁ39.8%£¬£¬
£¬Ô¤¼ÆÓ°ÏìÁè¼Ý7.4ÒÚ¶ùͯÇàÉÙÄê¡£Ïà½ÏÓÚÄк¢£¬£¬
£¬Å®º¢µÄ½üÊÓ»¼²¡ÂÊÔ¤¼Æ¸ü¸ß£¬£¬
£¬2050Ä꽫´ï42.0%¡£Óë6-12Ëê¶ùͯÏà±È£¬£¬
£¬13-19ËêÇàÉÙÄêµÄ½üÊÓ»¼²¡ÂÊÔ¤¼ÆÏÔןü¸ß£¬£¬
£¬2050Äê¿ÉÄܸߴï52.4%¡£ÓëÅ¹ú¼ÒÏà±È£¬£¬
£¬¿ªÕ¹Öйú¼Ò»ò²»Å¹ú¼ÒµÄ¶ùͯÇàÉÙÄêÔ¤¼ÆÓиü¸ßµÄ½üÊÓ»¼²¡ÂÊ£¬£¬
£¬2050Ä꽫µÖ´ï40.8%£»£»²¢ÇÒÑÇÖÞ½«ÊǽüÊÓ»¼²¡ÂÊ×î¸ßµÄµØÇø£¬£¬
£¬2050ÄêÔ¤¼Æ»¼²¡ÂÊΪ68.8%¡£

±í1 2030-2050ÄêÈ«Çò¶ùͯÇàÉÙÄê½üÊÓÊ¢ÐÐÇ÷ÊÆÔ¤²âÆÊÎö

±¾Ñо¿»ã×ÜÁËÈ«Çò¹æÄ£ÄÚ¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂʵÄ×îÐÂÖ¤¾Ý£¬£¬
£¬½ÓÄÉϵͳÐÔÒªÁì×ÛºÏÁ˹ØÓÚ½üÊÓ×ÜÌ廼²¡ÂʵÄÏêϸÊý¾Ý£¬£¬
£¬ÆÊÎöÆäÊ¢ÐÐÇ÷ÊƲ¢¾ÙÐÐδÀ´Ô¤²â¡£Ñо¿Í»³öÁËÈ«Çò²î±ðµØÇø¶ùͯÇàÉÙÄê½üÊÓ»¼²¡ÂʵIJî±ð£¬£¬
£¬²¢ÉîÈëÆÊÎöÁËÐԱ𡢡¢ÖÖ×åºÍµØÀíλÖõȶàÖÖÒòËضԽüÊÓ»¼²¡ÂʵÄÓ°Ïì¡£¸ÃÑо¿ÎªÈ«Çò¶ùͯÇàÉÙÄêÊÓÁ¦¿µ½¡ÏÖ×´ÌṩÁËÖÜÈ«µÄÖ¤¾Ý¡£Ñ­Ö¤Ö¤¾Ý½¨Ò飬£¬
£¬¶ùͯºÍÇàÉÙÄêÓ¦ÔöÌí»§Íâ»î¶¯£¬£¬
£¬ïÔÌ­ÆÁĻʱ¼ä¡£Ë¼Á¿µ½Éç»á¡¢¡¢¾­¼ÃºÍÎÄ»¯Åä¾°²î±ð£¬£¬
£¬ÔÚ¹«¹²ÎÀÉú¾öÒéÖУ¬£¬
£¬Ïà¹Ø²¿·ÖÓ¦µ±Ô½·¢ÖØÊÓÇøÓò»¯µÄ½üÊÓÔ¤·ÀÕ½ÂÔ£¬£¬
£¬ÒÔÔ½·¢ÓÐÕë¶ÔÐÔºÍÎÞаµÄ·½Ê½Ó¦¶ÔÈÕÒæÑÏÖصÄÊÓÁ¦¿µ½¡ÌôÕ½¡£

ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺ²©Ê¿ÉúÁº¾°ºê¡¢¡¢Ë¶Ê¿ÉúÆÕÓ­çù¡¢¡¢³Â¼ÑçùΪ±¾ÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬
£¬³ÂÑǾü½ÌÊÚΪÂÛÎĵÄΨһͨѶ×÷Õß¡£¸ÃÑо¿Êܵ½¹ú¼Ò×ÔÈ»¿ÆѧÏîÄ¿¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÏîÄ¿µÄÖ§³Ö¡£

ÂÛÎÄÁ´½Ó£ºhttps://bjo.bmj.com/content/bjophthalmol/early/2024/08/14/bjo-2024-325427.full.pdf